医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1593 医美概念股

休市中 01-10 16:00:00

530.408

-9.019

-1.67%

最高540.166	最低527.831	成交量2,076万
今开539.809	昨收539.428	日振幅2.29%
总市值0.00	流通市值0.00	总股本0.00
成交额1.25亿	换手率--	流通股本0.00
市净率1.07893	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":530.40845,"timestamp":1736496481989,"preClose":539.4278,"halted":0,"volume":20764805,"delay":0,"changeRate":-0.01672,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":-9.019348,"latestTime":"01-10 16:00:00","open":539.80853,"high":540.166,"low":527.8306,"amount":125439570,"amplitude":0.022868,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1736731800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1736472600000,1736481600000],[1736485200000,1736496000000]],"pbRate":1.07893,"peRate":19.523844,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1593","defaultTab":"news","newsList":[{"id":"2502950018","title":"康哲药业引进一款阿尔茨海默病新药 近年国内仅4款相关药物获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2502950018","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502950018?lang=zh_cn&edition=full","pubTime":"2025-01-10 21:19","pubTimestamp":1736515140,"startTime":"0","endTime":"0","summary":"2024年7月，ZUNVEYL获得美国食品药品监督管理局批准上市，为近十年来FDA批准的第二个阿尔茨海默病口服疗法。据新京报记者统计，近几年，国内仅有甘露特钠、氟[18F]贝他苯注射液、仑卡奈单抗、多奈单抗注射液4款相关药物获批上市。2024年1月5日，国家药监局批准仑卡奈单抗上市。记能达是一种用于静脉输注的药物，每四周注射一次，该产品已于2024年7月获FDA率先批准，用于治疗出现早期症状的阿尔茨海默病成年人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011021295495ff5c0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011021295495ff5c0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BYV24P56.USD","LU2488822045.USD","SG9999015945.SGD","SG9999015986.USD","SG9999015978.USD","IE00BMCWC346.EUR","00867","SG9999004220.SGD","BK1593","SG9999015952.SGD","BK1191"],"gpt_icon":0},{"id":"2502685873","title":"复星医药(02196)：复宏汉霖获注射用 HLX4联合斯鲁利单抗注射液治疗晚期/转移性实体瘤患者临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2502685873","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502685873?lang=zh_cn&edition=full","pubTime":"2025-01-10 18:23","pubTimestamp":1736504627,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，公司控股子公司复宏汉霖于近日收到国家药品监督管理局关于同意注射用 HLX43(即靶向 PD-L1 抗体-新型 DNA 拓扑异构酶 I 抑制剂偶联药物，注册分类：治疗用生物制品 1 类，以下简称“HLX43”)联合斯鲁利单抗注射液(中国境内商品名：汉斯状 )治疗晚期/转移性实体瘤患者开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展该治疗方案的 Ib/II 期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236168.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK0239","600196","BK0175","BK0188","BK0196","BK1576","02196","BK0060","BK1515","BK0028","BK1593","BK0096","BK1161","03347","BK0187","02696","BK1583","BK0012","BK1191","BK0183"],"gpt_icon":0},{"id":"2502885813","title":"复星医药(600196.SH)：注射用HLX43临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2502885813","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502885813?lang=zh_cn&edition=full","pubTime":"2025-01-10 18:18","pubTimestamp":1736504323,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(600196.SH)发布公告，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司(合称“复宏汉霖”)于近日收到国家药品监督管理局关于同意注射用HLX43(即靶向PD-L1抗体-新型DNA拓扑异构酶I抑制剂偶联药物，注册分类：治疗用生物制品1类，简称“HLX43”)联合斯鲁利单抗注射液(中国境内1商品名：汉斯状®)治疗晚期/转移性实体瘤患者开展临床试验的批准。复宏汉霖拟于条件具备后于中国境内开展该治疗方案的Ib/II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1141","BK0028","BK0096","BK0012","03347","BK0183","BK0196","BK1583","BK1191","600196","02196","BK0188","BK0060","BK0187","BK1515","BK1576","BK1593","BK0175"],"gpt_icon":0},{"id":"2502799837","title":"复星医药：控股子公司获药品临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2502799837","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502799837?lang=zh_cn&edition=full","pubTime":"2025-01-10 17:54","pubTimestamp":1736502840,"startTime":"0","endTime":"0","summary":"南方财经1月10日电，复星医药公告称，其控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司（合称“复宏汉霖”）近日收到国家药监局关于同意注射用HLX43（靶向PD-L1抗体-新型DNA拓扑异构酶I抑制剂偶联药物）联合斯鲁利单抗注射液（商品名：汉斯状®）治疗晚期/转移性实体瘤患者开展临床试验的批准。复宏汉霖拟于条件具备后在中国境内开展该治疗方案的Ib/II期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110175518a21cc059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110175518a21cc059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","02196","BK1515","BK1593","BK1141","03347","BK1576","BK1191"],"gpt_icon":0},{"id":"2502965588","title":"昊海生物科技1月10日耗资49.23万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2502965588","media":"格隆汇","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502965588?lang=zh_cn&edition=full","pubTime":"2025-01-10 17:20","pubTimestamp":1736500819,"startTime":"0","endTime":"0","summary":"格隆汇1月10日丨昊海生物科技(06826.HK)发布公告，2025年1月10日耗资49.23万港元回购2万股，回购价格每股24.45-24.7港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011017210298618e9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011017210298618e9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1161","06826"],"gpt_icon":0},{"id":"2502910834","title":"昊海生物科技(06826)1月10日斥资49.23万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2502910834","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502910834?lang=zh_cn&edition=full","pubTime":"2025-01-10 17:18","pubTimestamp":1736500702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2025年1月10日，该公司斥资49.23万港元回购2万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK1593","BK1161"],"gpt_icon":0},{"id":"2502385493","title":"四环医药1月10日收盘下跌3.33%，成交349.45万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502385493","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502385493?lang=zh_cn&edition=full","pubTime":"2025-01-10 17:11","pubTimestamp":1736500301,"startTime":"0","endTime":"0","summary":"1月10日，截至港股收盘，恒生指数下跌0.92%，报19064.29点。四环医药收报0.58港元/股，下跌3.33%，成交量595万股，成交额349.45万港元，振幅3.33%。最近一个月来，四环医药累计跌幅17.14%，今年来累计跌幅12.12%，跑输恒生指数-4.96%的跌幅。财务数据显示，截至2024年6月30日，四环医药实现营业总收入9.5亿元，同比减少10.04%；归母净利润-3342.4万元，同比增长32.67%；毛利率64.07%，资产负债率55.85%。资料显示，四环医药控股集团有限公司成立于2001年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011017140998618ca1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011017140998618ca1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1600","BK1593","00460","BK1515"],"gpt_icon":0},{"id":"2502834807","title":"现代牙科(03600)1月10日斥资40.74万港元回购10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2502834807","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502834807?lang=zh_cn&edition=full","pubTime":"2025-01-10 17:10","pubTimestamp":1736500208,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代牙科(03600)发布公告，于2025年1月10日该公司斥资40.74万港元回购10万股，回购价格为每股4.04-4.08港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1100","03600","BK1593"],"gpt_icon":0},{"id":"2502665850","title":"RSV疫苗被要求增加风险警告；康哲药业引进阿尔茨海默病口服药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2502665850","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502665850?lang=zh_cn&edition=full","pubTime":"2025-01-10 16:52","pubTimestamp":1736499130,"startTime":"0","endTime":"0","summary":"RSV疫苗再遭“打击”。日前，FDA 发布公告，要求辉瑞和GSK对其已被批准上的RSV疫苗的标签进行修改，添加有关吉兰-巴雷综合征风险的新警告。1月8日，康哲药业宣布，通过全资附属公司与Alpha Cognition就用于治疗轻度至中度阿尔茨海默型痴呆症状的改良型新药ZUNVEYL签订许可、合作与经销协议，获得了在亚洲（除日本）、澳洲、新西兰开发、注册、生产、进口、出口和商业化产品的独家权利，Alpha公司保留在区域内生产供应的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011016521495ff09f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011016521495ff09f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","SG9999015978.USD","00867","IE00BMCWC346.EUR","SG9999015986.USD","IE00BYV24P56.USD","SG9999015945.SGD","BK1191","SG9999015952.SGD","LU2488822045.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2502233836","title":"复星医药01月10日遭主力抛售281万元 环比增加119.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502233836","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502233836?lang=zh_cn&edition=full","pubTime":"2025-01-10 16:15","pubTimestamp":1736496923,"startTime":"0","endTime":"0","summary":"01月10日, 复星医药股价跌1.94%，报收13.16元，成交金额3124万元，换手率0.43%，振幅2.83%，量比1.29。复星医药今日主力资金净流出281万元，连续4日净流出，上一交易日主力净流出128万元，今日环比增加119.53%。近一年数据显示，该股主力连续4日净流出后，次日下跌概率为71.43%，平均跌幅为1.93%。该股近5个交易日下跌3.51%，主力资金累计净流出724万元；近20日主力资金累计净流出2778万元，其中净流出天数为13日。该股主力净额占比0.04%，港股市场排名2541/2655。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110161539aba59b85&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110161539aba59b85&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02196","BK1515","BK1593"],"gpt_icon":0},{"id":"2502386944","title":"复锐医疗科技盘中异动 临近收盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2502386944","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502386944?lang=zh_cn&edition=full","pubTime":"2025-01-10 15:46","pubTimestamp":1736495167,"startTime":"0","endTime":"0","summary":"2025年01月10日临近收盘15时46分，复锐医疗科技股票出现波动，股价急速跳水5.03%。截至发稿，该股报3.400港元/股，成交量33.4万股，换手率0.07%，振幅4.75%。复锐医疗科技股票所在的医疗设备及用品行业中，整体跌幅为0.12%。其相关个股中，中国卫生集团、GUANZE MEDICAL、紫元元涨幅较大，振幅较大的相关个股有中国卫生集团、加和国际控股、华检医疗，振幅分别为18.33%、13.53%、12.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011015460798616eca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011015460798616eca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1100","BK1593","BK1585","01696"],"gpt_icon":0},{"id":"2502869271","title":"瑞丽医美盘中异动 下午盘股价大跌6.86%报0.095港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502869271","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502869271?lang=zh_cn&edition=full","pubTime":"2025-01-10 13:37","pubTimestamp":1736487455,"startTime":"0","endTime":"0","summary":"2025年01月10日下午盘13时37分，瑞丽医美股票出现异动，股价急速跳水6.86%。截至发稿，该股报0.095港元/股，成交量25.4万股，换手率0.05%，振幅5.88%。资金方面，该股资金流入0港元，流出2.506万港元。瑞丽医美股票所在的医疗及医学美容服务行业中，整体跌幅为0.35%。其相关个股中，脑动极光-B、德视佳、百本医护涨幅较大，振幅较大的相关个股有雍禾医疗、脑动极光-B、健康之路，振幅分别为19.77%、18.20%、9.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011013373595fecde9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011013373595fecde9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02135","BK1593","BK1209"],"gpt_icon":0},{"id":"2502002876","title":"高途集团签约上海复星体育集团，整合资源深化体育+教育融合发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2502002876","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502002876?lang=zh_cn&edition=full","pubTime":"2025-01-10 11:43","pubTimestamp":1736480612,"startTime":"0","endTime":"0","summary":"2025年1月9日，高途教育科技集团与上海复星体育集团正式签署战略合作协议。凭借高途集团和复兴体育在各自领域的客户基础、资源优势及储备，未来，双方将秉持“探索文化与体育产业协同发展新范式”这一原则，在多个维度开展合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011011434795feb3bb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025011011434795feb3bb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2502006435","title":"复星医药治疗乳腺癌创新药上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2502006435","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502006435?lang=zh_cn&edition=full","pubTime":"2025-01-10 10:32","pubTimestamp":1736476370,"startTime":"0","endTime":"0","summary":"该新药联合氟维司群用于治疗既往接受内分泌治疗后出现疾病进展的激素受体阳性、人表皮生长因子受体2阴性的局部晚期或转移性乳腺癌的药品注册申请也已于2023年11月获国家药监局受理。作为复星医药控股子公司，奥鸿药业持续丰富创新产品管线，聚焦差异化、高技术壁垒的产品研发，不断提升管线价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/10103247327307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["159992","BK0060","06978","BK0188","BK0239","600196","BK1515","BK1191","BK0096","02196","BK0175","BK1161","BK0028","BK1574","BK0183","BK1593","BK0196","BK0187","BK0012"],"gpt_icon":0},{"id":"2502072421","title":"现代牙科完成收购泰国牙科实验室Hexa Ceram74%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2502072421","media":"新浪港股","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502072421?lang=zh_cn&edition=full","pubTime":"2025-01-10 08:48","pubTimestamp":1736470080,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　现代牙科（03600）发布公告，根据该等买卖协议条款，完成A及完成B的所有先决条件已获达成，且完成A及完成B已于2025年1月9日同时进行。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-01-10/doc-ineemwnf2483739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1593","03600","BK1583","BK1100"],"gpt_icon":0},{"id":"2502042074","title":"康哲药业引进阿尔茨海默症新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2502042074","media":"深圳商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502042074?lang=zh_cn&edition=full","pubTime":"2025-01-10 01:05","pubTimestamp":1736442352,"startTime":"0","endTime":"0","summary":"【深圳商报讯】（记者钟国斌）1月8日，康哲药业（00867.HK）发布公告称，公司通过全资附属公司与AlphaCognitionInc.（“Alpha”）就用于治疗轻度至中度阿尔茨海默型痴呆症状的改良型新药ZUNVEYL签订许可、合作与经销协议。根据协议，公司获得ZUNVEYL在亚洲（除日本）、澳大利亚、新西兰开发、注册、生产、进口、出口和商业化产品的独家权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501103292729771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999015978.USD","SG9999015945.SGD","IE00BMCWC346.EUR","BK1191","SG9999015952.SGD","00867","BK1593","SG9999015986.USD","IE00BYV24P56.USD","LU2488822045.USD","SG9999004220.SGD"],"gpt_icon":0},{"id":"2502504194","title":"复星医药(02196.HK)子公司新药注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2502504194","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502504194?lang=zh_cn&edition=full","pubTime":"2025-01-10 00:26","pubTimestamp":1736439960,"startTime":"0","endTime":"0","summary":"复星医药(02196.HK) 公布，控股子公司就锦州奥鸿药业就枸橼酸伏维西利胶囊的药品注册申请获国家药品监督管理局受理，本次申报适应症为用于激素受体阳性、人表皮生长因子受体2阴性的局部晚期或转移性乳腺癌，应与芳香化酶抑制剂联合使用作为绝经前、绝经后、围绝经期女性乳腺癌患者的初始内分泌治疗。该新药为集团拥有自主知识产权的创新型小分子CDK4/6抑制剂，拟用于晚期转移性实体瘤治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-09 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220221174705869_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1409275/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["600196","02196","BK0096","BK0239","BK0028","BK0012","BK0183","BK0060","BK0187","BK0188","BK0196","BK1191","BK1515","BK1593","BK0175"],"gpt_icon":0},{"id":"2502604104","title":"现代牙科完成收购HexaCeram 74%股份交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2502604104","media":"财中社","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502604104?lang=zh_cn&edition=full","pubTime":"2025-01-09 19:28","pubTimestamp":1736422080,"startTime":"0","endTime":"0","summary":"财中社1月9日电现代牙科（03600）发布公告，宣布完成收购目标公司74%股份的交易。该交易涉及Hexa Ceram Company Limited，董事会确认根据买卖协议的条款，所有先决条件已达成，并于2025年1月9日同时完成。完成后，买方及Meekiatichaikun分别持有目标公司16万股和5.46万股股份，分别占目标公司已发行股本的74%和26%。因此，目标公司已成为公司的非全资附属公司，其财务业绩将纳入公司的财务报表中。此外，股东协议及期权协议也于同日生效，对各方具有约束力。（文章来源：财中社）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109193357986063c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250109193357986063c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03600","BK1583","BK1100","BK1593"],"gpt_icon":0},{"id":"2502049850","title":"4400万美元买断阿尔兹海默症新药 康哲药业能否抢滩成功？","url":"https://stock-news.laohu8.com/highlight/detail?id=2502049850","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502049850?lang=zh_cn&edition=full","pubTime":"2025-01-09 19:11","pubTimestamp":1736421060,"startTime":"0","endTime":"0","summary":"目前获FDA批准上市的阿尔茨海默病药物不超十款，国产药物更是一片空白。2019年，绿谷制药研发的原创治疗阿尔茨海默病新药“九期一”上市。此次康哲药业拿下的ZUNVEYL于2024年7月获得美国FDA批准上市，为近十年来FDA批准的第二个阿尔茨海默病口服疗法。这一预期，充分说明了中国患者对阿尔茨海默病药物的迫切需求。目前，先声药业、恒瑞医药、海正药业、通化金马的阿尔茨海默病相关药物都已进入临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010919182395fde5b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010919182395fde5b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","SG9999015978.USD","BK1191","LU2488822045.USD","SG9999004220.SGD","00867","IE00BYV24P56.USD","SG9999015986.USD","IE00BMCWC346.EUR","SG9999015952.SGD","SG9999015945.SGD"],"gpt_icon":0},{"id":"2502097724","title":"现代牙科(03600)完成收购泰国牙科实验室Hexa Ceram74%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2502097724","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502097724?lang=zh_cn&edition=full","pubTime":"2025-01-09 19:06","pubTimestamp":1736420806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，现代牙科(03600)发布公告，根据该等买卖协议条款，完成A及完成B的所有先决条件已获达成，且完成A及完成B已于2025年1月9日同时进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1235661.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03600","BK1583","BK1593","BK1100"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0352},{"period":"1month","weight":-0.0541},{"period":"3month","weight":-0.1029},{"period":"6month","weight":0.0421},{"period":"1year","weight":0.1694},{"period":"ytd","weight":-0.0496}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1593","nameEN":"BK1593"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"医美概念股,BK1593,医美概念股股票,医美概念股股票老虎,医美概念股股票老虎国际,医美概念股行情,医美概念股股票行情,医美概念股股价,医美概念股股市,医美概念股股票价格,医美概念股股票交易,医美概念股股票购买,医美概念股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"医美概念股(BK1593)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供医美概念股(BK1593)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}